Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Hanmi Pharmaceutical Co., Ltd.

Home Clinical Trial Sponsors and OrganizationsHanmi Pharmaceutical Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

ACTIVE

首尔特别市, South Koreawww.hanmipharm.comPublic5,001–10,000 employeesEstablished: 1973-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

25

22 active

Approvals

4

Total approvals

Agencies

1

Regulatory bodies

Founded

1973

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

32.0%

Phase 2

2

8.0%

Trial Status Distribution

Active, not recruiting

22

88.0%

Completed

2

8.0%

Withdrawn

1

4.0%

Clinical Trials

Trials sponsored by this organization (25)

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure

Active, not recruiting

Dec 202218 participants

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure

Active, not recruiting

Jul 202218 participants

Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure

Active, not recruiting

May 202118 participants

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise(AMPLITUDE-M)

Active, not recruiting

Feb 2018800 participants

A study to assess effects (how safe and effective) of HM61713 (BI 1482694) (new medicine) on specific type of non-small cell lung cancer, which characterized by being positive to certain type of mutation (T790M) , after treatment with a class of drugs known as (EGFR-TKI). The study will also test the drug concentrations’ changes in the patient blood at certain time points.

Active, not recruiting

Dec 2015150 participants

A study to assess effects (how safe and effective) of HM61713 (new medicine) on specific type of non-small cell lung cancer, which characterized by being positive to certain type of mutation (T790M) , after treatment with a class of drugs known as (EGFR-TKI). The study will also test the drug concentrations´changes in the patient blood at certain time points.

Active, not recruiting

Jul 2015160 participants

A 16 weeks study to assess effects (how safe and effective) of HM11260c (new medicine) on blood sugar, the study will compare three dose of HM11260c against placebo (dummy drug). This study will take place in many centers across the world. Both the doctors and the patients will not know which patient is getting HM11260c at what strength or placebo.

Active, not recruiting

Jan 2014200 participants

A 16 weeks study to assess effects (how safe and effective) of HM11260c (new medicine) on blood sugar, the study will compare three dose of HM11260c against placebo (dummy drug). Both the doctors and the patients will not know which patient is getting HM11260c at what strength or placebo.

Active, not recruiting

Jan 2014200 participants

Page 1 of 4

Approvals

Approvals by Agency

PHILIPPINES

Philippines FDA

4

Approvals

Recent Approvals

News

Novo Nordisk and Eli Lilly File for South Korean Approval, Setting Up Launch Race Next Year

- Novo Nordisk has filed Wegovy Pill (semaglutide) and Eli Lilly has filed Foundayo (orforglipron) for South Korean marketing authorization with the Ministry of Food and Drug Safety. - Both oral candidates launched in the US at $149 per month at the starting dose, roughly 85% below the $1,000 US starting price of injectable Wegovy and Mounjaro. - Hanmi Pharmaceutical targets October approval for its injectable EPPE, which cut weight 9.75% at 40 weeks in a 448-patient South Korean Phase 3 trial.

On this page

Overview
Clinical Trials25
Approvals4
News1

Back to Organizations